In pharma, AI isn’t defined by what it can do. It’s defined by what it can prove.
AI adoption is no longer a question of potential. It is a question of performance.
Most pharmaceutical organizations are already investing in AI. Adoption is widespread. Impact is not.
The challenge
AI is advancing quickly, but enterprise progress remains uneven.
What works in isolated use cases does not always hold across the business. Outputs may improve, but consistency, control, and scalability remain unresolved.
The result is a growing divide between activity and outcome.
What you will gain from this POV
This POV examines what is changing in how AI is applied across pharmaceutical commercialization.
It challenges common assumptions, surfaces where approaches begin to break and outlines the conditions under which AI can move beyond experimentation.
Explore our model to see how this approach is being applied in practice.
Why it matters
This is no longer a theoretical shift.
Decisions made now around how AI is built, deployed and integrated will determine whether it becomes a source of advantage or another layer of complexity.
Download the full POV.
Author Team
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…